We use cookies to give you a better Web experience. By visiting our website you agree to our use of cookies. Read about cookies
OK
  1. Home
  2. Mandates
  3. Vinge advised Forbion Capital Partners in connection with investment in Cadoz AB

Mandate Vinge advised Forbion Capital Partners in connection with investment in Cadoz AB

May 10, 2010

Cardoz AB based in Stockholm has received a capital injection of SEK 100 million. The investment has been made by the Dutch venture capital company, Forbion Capital Partners and the Spanish venture capital company, Ysios Capital Partners together with the existing owner the Swedish venture capital company, HealthCap, which also helped to start the company.

Cardoz develops anti-inflammatory pharmaceuticals to combat heart and vascular disorders. The capital contribution is primarily intended for the execution of a clinical phase II trial of a new drug to combat abdominal aorta aneurism (AAA). At present there are no drugs which combat AAA.

Vinge’s team consisted of responsible partner Johan Winnerblad and Johan Larsson who acted as project manager.

Clarification of the interpretation of ”nearest suitable railway station”

 Road transport performed by Samskip Sia in Sweden has been confirmed to be within the framework of a permitted combined transport through a decision of the Administrative court of Falun in Sweden. The central question in the case was how to interpret the term “nearest suitable railway station”
June 30, 2020

DAC 6 – EU Directive concerning reportable cross‑border tax arrangements

 DAC 6 is a EU Directive which entails that advisers are subject to a duty to notify the relevant tax authorities concerning their client’s cross‑border arrangements. The purpose of the information disclosure obligation is to combat tax evasion, tax fraud and tax avoidance.
June 04, 2020

The importance of continuous focus on compliance procedures in disrupting times

 A large number of corporations will most certainly be severely impacted by the effects of the Covid-19 pandemic. The new challenges will impact companies’ compliance risks, which are likely to be different and, to a certain extent, increased. It is crucial that - also in disrupting times - internal compliance procedures are maintained and that new risks are identified and mitigated.
May 28, 2020